JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


The Journal of Nuclear Medicine Vol. 15 No. 10 884-886
© 1974 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Alazraki, N. P.
Right arrow Articles by Ashburn, W. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alazraki, N. P.
Right arrow Articles by Ashburn, W. L.

Differences in Choroid Plexus Concentration of Pertechnetate Produced by Varying Time of Pertechnetate Administration and Brain Imaging

Naomi P. Alazraki, Richard L. Littenberg, Sheldon Hurwitz, Ray R. Quinto, Samuel E. Halpern and William L. Ashburn

Veterans Administration Hospital and University California School of Medicine, San Diego, California

Correspondence: For reprints contact: Naomi Alazraki, V.A. Hospital, 3350 LaJolla Village Dr., San Diego, Calif. 92161.

ABSTRACT

To block effectively the uptake of pertechnetate by the choroid plexus, perchlorate may be given orally at any time before or after the injection of 99mTc-pertechnetate if administration precedes imaging by at least 60 min. Possible routes of discharge of pertechnetate from the choroid plexuses are back into the blood directly or indirectly through secretion with newly formed CSF.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1974 by the Society of Nuclear Medicine.